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A B S T R A C T
Objectives: Antimicrobial stewardship (AMS) programmes are well established in hospitals, yet such
programmes have not been widely implemented in the community. Understanding current practices and
perceptions of community pharmacists about AMS may provide insights into the implementation of AMS
in community pharmacies. The aims of this study were to validate a questionnaire to measure
community pharmacists’ perceptions of AMS and to explore barriers and facilitators to their involvement
in community-based AMS initiatives.
Methods: A 44-item survey questionnaire comprising sections on demographics, AMS practices and
perceptions of community pharmacists, and barriers and facilitators to AMS was hosted online.
Community pharmacists were recruited through social media pages of community pharmacist groups
across Australia. Cronbach’s alpha and exploratory factor analysis were used to measure the reliability
and validity of the survey tool, respectively.
Results: A total of 330 community pharmacists started the survey, with 255 of them completing at least
one question. Pharmacists were more likely to intervene with general practitioners (GPs) (80% of the
time) for allergies, dosing and drug interactions and were less likely to intervene if they felt the choice of
antibiotic was inappropriate (45%). Major barriers limiting pharmacists’ participation in AMS were lack of
access both to patient data (82.6%) and to a standard guideline to implement AMS programmes (72.1%).
Almost all pharmacists (98%) reported that better collaboration with GPs would improve their
participation in AMS initiatives.
Conclusion: Future studies utilising the knowledge gained from this study may provide a framework for
AMS in community pharmacy settings.
© 2019 International Society for Antimicrobial Chemotherapy. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The World Health Organization (WHO) has declared antimicro-
bial resistance (AMR) a major global threat. One of the strategies to
reduce AMR is to control inappropriate use of antimicrobials [1].
Antimicrobial stewardship (AMS) is a set of co-ordinated
interventions and initiatives to promote the appropriate and
judicious use of antimicrobials without compromising patients’
quality of healthcare [2]. The Australian Commission on Safety and
Quality in Health Care (ACSQHC) recommends AMS programmes
(ASPs) in hospitals [3], and pharmacists have a routine and
recognised role in these programmes [4].* Corresponding author.
E-mail address: tasneem.rizvi@utas.edu.au (T. Rizvi).
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2213-7165/© 2019 International Society for Antimicrobial Chemotherapy. Published by
creativecommons.org/licenses/by-nc-nd/4.0/).However, AMR is becoming a growing concern in the
community, which is where most antimicrobials (88%) are
prescribed, and one-half of these prescriptions are considered
inappropriate [2]. Hence, there is an urgent need for engaging
suitable resources and stakeholders, including community phar-
macists, to support the implementation of such AMS initiatives in
the community. Community pharmacists are currently offering
several professional services such as health screening, vaccination
and chronic disease management, suggesting their desire and
willingness to translate their traditional supply-centred role into a
more advanced clinical role [5,6].
There is an unmet need to ensure that measures are in place for
effective participation of community pharmacists in AMS activities
[6,7]. Therefore, to assess the current knowledge and perception of
community pharmacists regarding AMS, we developed and tested
a questionnaire in one state of Australia (Tasmania) [8]. The Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
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need to validate the questionnaire on a larger scale. Hence, the
objectives of this study were to implement and test the survey
questionnaire at a national level in order to identify gaps in
knowledge and to explore community pharmacists’ current
practices and perceptions regarding AMS.
2. Methods
2.1. Questionnaire
Data were collected through an online questionnaire that was
developed and tested in another similar, but smaller, study (Fig. 1),
details of which have been published elsewhere [8]. In brief, theFig. 1. Development of the questionnaire.44-item survey questionnaire, comprising sections on: demo-
graphics; current AMS practices; the perceived importance of,
barriers to and facilitators of AMS; as well as a section about the
awareness of NPS MedicineWise initiatives (see Appendix 1). NPS
MedicineWise is an Australian not-for-profit independent organi-
sation that is leading national initiatives to reduce inappropriate
antibiotic prescribing [9]. The MedicineInsight programme, Resis-
tance Fighter campaign and Antibiotic Awareness Day are some of
the key initiatives of NPS MedicineWise to make stakeholders
aware of the AMR threat and to educate them regarding rational
antibiotic use [9].
2.2. Survey implementation
The survey was hosted on the web survey platform Lime-
Survey1, which is an open-source survey tool, between November
2016 to February 2017 [10]. Community pharmacists were invited
through e-mails to the leading pharmacy chain stores and the
Pharmaceutical Society of Australia. Advertisements on Facebook
pages of pharmacist communities representing various states of
Australia were also posted. The invitation e-mails and advertise-
ments contained a link to the questionnaire along with a mobile-
enabled scanning code (QR code) and details on how to enter a
draw to win one of twenty A$50 gift cards. At the end of the survey,
the winners of the draw were randomly selected.
2.3. Data analysis
Data collected via LimeSurvey1 was exported to Microsoft
Excel1 (Microsoft Corp., Redmond, WA, USA) and IBM SPSS
Statistics v.22 (IBM Corp., Armonk, NY, USA) for analysis. A mixed
methods approach was adapted to analyse the results of different
sections of the survey. Demographics were tabulated as numbers,
frequencies, percentages and averages. Principal axis factoring
(PAF) technique was used to determine the validity of perception
scales, namely perceived importance of, barriers to implementa-
tion and facilitators of AMS in community pharmacies. Cronbach’s
alpha (α) was used to determine the reliability of the identified
factors.
3. Results
3.1. Demographics
Table 1 presents the demographic characteristics of the
community pharmacists who participated in the survey. A total
of 330 community pharmacists accepted the invitation by clicking
on the link, with 255 of them completing at least one question (as
participants were able to skip questions). There was a proportion-
ate distribution of responses from different Australian states and
territories, with the majority (69.3%) from metropolitan areas. The
median age of respondents was 29 years and their median
experience was 6 years. The majority (74%) of participants felt that
they were aware of the term ‘AMS’, although 86% of them reported
a better understanding of AMS after reading the formal definition.
3.2. Awareness of the national quality initiatives
Most of the respondents knew about the resources provided by
NPS MedicineWise related to rational use of antibiotics (74%) and
were aware that NPS MedicineWise has dedicated 1 week for
antibiotic awareness (73%). Most respondents knew about the
‘Resistance Fighter’ campaign co-ordinated by NPS MedicineWise
(62%). However, fewer respondents reported using the patient
education resources available from the NPS MedicineWise website
(39%), whilst some respondents were not even aware that such
Table 1
Demographic characteristics of survey respondents (N = 255).
Characteristic n (%)
Sex (N = 227)
Male 78 (34.4)
Female 148 (65.2)
Prefer not to disclose 1 (0.4)
State/territory (N = 228)
NSW 62 (27.2)
QLD 54 (23.7)
VIC 45 (19.7)
ACT 6 (2.6)
SA 20 (8.8)
WA 28 (12.3)
TAS 8 (3.5)
NT 5 (2.2)
Highest level of pharmacy education completed (N = 229)
Bachelor’s degree 177 (77.3)
Master’s degree 33 (14.4)
Doctorate degree 3 (1.3)
Other 16 (7.0)
Age (N = 225) Median 29 years (IQR 26–36 years)
Experience (N = 225) Median 6 years (IQR 4–12 years)
Geographical location of work (N = 228)
Metropolitan 158 (69.3)
Rural 63 (27.6)
Remote 7 (3.1)
IQR, interquartile range; NSW, New South Wales; QLD, Queensland; VIC, Victoria;
ACT, Australian Capital Territory; SA, South Australia; WA, Western Australia; TAS,
Tasmania; NT, Northern Territory.
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positively regarding the likelihood of pharmacies utilising the
resources provided by the NPS MedicineWise (61%).
3.3. Current practices
The most frequent AMS activities reported by community
pharmacists were contacting the prescriber about drug interac-
tions (95.2%), allergies (98.4%) and antibiotic doses (83.8%)
(Table 2). Pharmacists were less likely (44.8%) to contact
prescribers if they considered the selection of an antibiotic to be
inappropriate. Most of the respondents reported that they
frequently guided patients regarding over-the-counter treatment
options (88.9%) and referred patients to a general practitioner (GP)
if symptoms were suggestive of infection (76.6%) (Table 2).
Participants reported that they frequently provide clear messages
on expected side effects (80.0%), however comparatively fewer
reported that they explain what should be done if a patient
experiences a side effect (74.5%). Similarly, most of the respondents
frequently advise patients when it is appropriate to use an
antibiotic repeat (85.1%), but fewer reported that they discuss withTable 2
IQR of item scales: current antimicrobial stewardship (AMS) practices in community p
Scale/item 
Providing clear messages on expected side effects (n = 255) 
Providing clear messages on what should be done if a patient experiences a side effe
Contacting the prescriber if the patient is allergic to the prescribed antibiotic (n = 25
Contacting the prescriber if the antibiotic dose/frequency is too high or too low (n =
Contacting the prescriber if the prescribed antibiotic involves a drug interaction (n =
Contacting the prescriber if the choice of antibiotic may not be optimal (n = 250) 
Recommending OTC/self-care treatment to patients with symptoms of infection not 
Referring patients to a GP when symptoms are suggestive of an infection (n = 253) 
Providing advice on when it would be appropriate to use the repeat prescription (n 
Discussing with patient to determine whether it is appropriate for them to use the p
IQR, interquartile range; OTC, over-the-counter; GP, general practitioner.
a Current practices measured on a scale of 1–5, where 1 = do not practice at all andpatients the appropriateness of a repeat antibiotic prescription at
the time of dispensing (68.5%).
3.4. Validity and reliability of the perception scales
The survey results related to perception scales are outlined in
Tables 3 and 4. The values of the Kaiser–Meyer–Olkin test and
Bartlett’s test of sphericity were 0.53 and P < 0.001, respectively,
indicating the suitability of exploratory factor analysis (EFA) in the
study sample [11] (see Appendix 2). PAF was used for extraction,
and Oblimin with Kaiser Normalisation was used as a rotation
technique. The rotated solution for the three perception scales
yielded four factors: perceived importance of AMS, comprising 5
items (Cronbach’s α = 0.787); perceived operational barriers to
AMS, comprising 3 items (Cronbach’s α = 0.637); perceived barriers
related to GPs’ support, comprising 3 items (Cronbach’s α = 0.740);
and perceived facilitators, comprising 6 items (Cronbach’s α =
0.671) (see Appendix 2). The item related to monetary compensa-
tion did not load on any factor but was kept as a standalone item
owing to its support in the qualitative data and as per the authors’
opinion.
3.5. Perceived importance
Most respondents (94.8%) agreed that community pharmacists
could play a vital role in implementing AMS in the community
setting. Furthermore, a similar proportion of respondents per-
ceived that the associated healthcare costs would be decreased
(93.1%) and that inappropriate use of antibiotics would be reduced
(91.9%) by improved community AMS. Pharmacists indicated that
AMS initiatives in the community setting would increase job
satisfaction (83.3%) and enhance the public image (80.9%) of
community pharmacists.
3.6. Perceived barriers
The major barriers identified by the respondents were lack of
access to patients’ records to review the appropriateness of
antibiotic prescriptions (82.6%) and lack of access to standard
guidelines to implement AMS. Most pharmacists believed GPs are
not receptive when pharmacists intervene regarding the choice of
antibiotic (78.3%). However, most respondents did not consider
lack of time (60.3%) or lack of training (54.4%) as barriers to AMS
activities.
3.7. Perceived facilitators
The major facilitator identified by the respondents in carrying
out AMS activities in the community was better collaboration withharmacies.a
Participant’s response
[n (%)]
Median
(IQR)
Scoring 3 Scoring 4
51 (20.0) 204 (80.0) 4 (4–5)
ct (n = 255) 65 (25.5) 190 (74.5) 4 (3–5)
2) 4 (1.6) 248 (98.4) 5 (5–5)
 253) 41 (16.2) 212 (83.8) 5 (4–5)
 251) 12 (4.8) 239 (95.2) 5 (5–5)
138 (55.2) 112 (44.8) 3 (2–4)
needing antibiotics (n = 252) 28 (11.1) 224 (88.9) 5 (4–5)
6 (2.4) 247 (97.6) 5 (5–5)
= 255) 38 (14.9) 217 (85.1) 4 (4–5)
resented repeat prescription (n = 254) 80 (31.5) 174 (68.5) 4 (3–5)
 5 = practice all the time.
Table 3
IQR of item scales: perceived importance of and barriers to antimicrobial stewardship (AMS) in community pharmacies.a
Scale/item Participant’s response [n (%)] Median (IQR)
Scoring 4 Scoring 5
Perceived importance of AMS
Community pharmacists can play an important role in AMS (n = 248) 13 (5.2) 235 (94.8) 6 (5–7)
AMS will reduce healthcare costs associated with infections (n = 247) 17 (6.9) 230 (93.1) 7 (6–7)
AMS will enhance the public image of pharmacists (n = 246) 47 (19.1) 199 (80.9) 6 (5–7)
AMS will enhance the job satisfaction of pharmacists (n = 245) 41 (16.7) 204 (83.3) 6 (5–7)
AMS will reduce inappropriate antibiotic use (n = 248) 20 (8.1) 228 (91.9) 6.5 (5–7)
Perceived barriers to AMS: operational barriers
I do not have the required training to participate in AMS (n = 239) 130 (54.4) 109 (45.6) 4 (3–5)
I do not have enough time to participate in AMS (n = 239) 144 (60.3) 95 (39.7) 4 (3–5)
Limited access to patients’ records to review appropriateness of antibiotic prescriptions (n = 241) 42 (17.4) 199 (82.6) 6 (5–7)
There are no standard guidelines to implement AMS (n = 233) 65 (27.9) 168 (72.1) 5 (4–6)
Perceived barriers to AMS: perceived support from GPs
GPs are not receptive to pharmacists intervening on the choice of antibiotic (n = 240) 52 (21.7) 188 (78.3) 6 (5–7)
GPs are not receptive to pharmacists intervening on the dose and dosage form of antibiotic (n = 240) 86 (35.8) 154 (64.2) 5 (4–6)
GPs are not receptive to pharmacists intervening on the duration of antibiotic (n = 240) 86 (35.8) 154 (64.2) 5 (4–6)
IQR, interquartile range; GP, general practitioner.
a Perceived importance and barriers were measured on a scale of 1–7, where 1 = strongly disagree and 7 = strongly agree.
Table 4
IQR of item scales: perceived facilitators of antimicrobial stewardship (AMS) in community pharmacies.a
Item Participant’s response [n (%)] Median (IQR)
Scoring 3 Scoring 4
Increased provision of education activities regarding AMS (n = 234) 22 (9.4) 212 (90.6) 4 (4–5)
Public awareness initiatives highlighting community pharmacists in AMS (n = 234) 11 (4.7) 223 (95.3) 5 (4–5)
Access to guidelines for common community infections (n = 232) 6 (2.6) 226 (97.4) 5 (4–5)
Better collaboration with local GP practices (n = 234) 4 (1.7) 230 (98.3) 5 (4–5)
Clarification of the duties of pharmacists’ professional organisations (n = 229) 38 (16.6) 191 (83.4) 4 (4–5)
Better access to patients’ clinical and laboratory data (n = 234) 16 (6.8) 218 (93.2) 5 (4–5)
Monetary compensation for the time involved in AMS programmes (n = 231) 29 (12.6) 202 (87.4) 5 (4–5)
IQR, interquartile range; GP, general practitioner.
a Perceived facilitators measured on a scale of 1–5, where 1 = unhelpful and 5 = most helpful.
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questions about barriers, pharmacists reported that facilitators
would be the availability of one standard antibiotic guideline for
prescribers and pharmacists, access to patients’ clinical and
laboratory data, public awareness campaigns, and provision of
AMS-related educational activities for community pharmacists.
Other facilitators considered somewhat helpful included monetary
compensation and clarification of AMS duties expected of
pharmacists by their professional organisations.
3.8. Qualitative analysis
A thematic analysis of the qualitative comments is presented in
Appendix 3. The major issues highlighted by the respondents in
carrying out routine AMS activities included: lack of access to
patients’ records and laboratory data; inappropriate use of
antibiotic repeats; use of different antibiotic guidelines by
prescribers; and lack of clarity regarding the AMS role of
community pharmacists. Respondents further stressed that their
limited role in AMS is due to lack of access to patients’ records,
which causes uncertainty as to why an antibiotic is in a given dose,
dosage form and duration, hence they hesitate to intervene.
Respondents also pointed out limited public awareness regarding
AMR that leads to unnecessary demand for repeat antibiotic
prescriptions. They specifically pointed out inconsistencies and
apparent mistakes in doses prescribed for paediatric patients.
Participants also pointed out operational limitations in carrying
out AMS-related activities and they suggested that community
pharmacists should be professionally recognised and compensated
for the provision of AMS services. Participants reported that
unnecessary prescribing of and consumer demand for antibiotics isgradually decreasing, but that this could be further reduced if a
comprehensive AMS model is introduced in the community.
4. Discussion
The proven benefits of pharmacists in ASPs in hospital settings
suggest that they can also play an important role in community
pharmacy AMS services [12–15]. Whilst pharmacists are willing to
contribute to AMS [16], so far the majority of AMS studies involving
primary care interventions have been aimed only at GPs working in
the USA, Europe or North America [17]. The results of the present
study provide an insight into the AMS knowledge as well as the
current practices and perceptions of Australian community
pharmacists. A mixed methods approach was used to validate
the survey tool developed in the pilot study published elsewhere
[18]. Reliability analysis and EFA helped to examine the internal
structure of the questionnaire.
4.1. Main findings
The results of this national study found that the majority of
Australian community pharmacists are aware of the term ‘AMS’
but do not have an in-depth understanding of it. They need better
access to AMS educational resources provided by the pharmaceu-
tical bodies and agencies tasked with improving quality use of
medicine, such as NPS MedicineWise. The study found that the
majority of pharmacists perceive that the AMS resources of NPS
MedicineWise are not effectively promoted and they are unable to
easily access them. AMS education, policies and regulations in
community settings are still evolving in other countries as well.
According to the US Society of Infectious Diseases Pharmacists
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ASPs and, without relevant knowledge of AMS, community
pharmacists cannot play their desired role [6,19]. The current
findings are in accordance with other studies in which community
pharmacists were found to be willing to participate in educational
activities related to AMS [20,21]. However, AMS-related educa-
tional intervention studies involving implementation of antibiotic
guidelines, diagnostic skills and communication skills focus only
on clinics and prescribers practicing in them, and there is a paucity
of data regarding the role of community pharmacists in AMS [6].
While carrying out their routine pharmacy activities, most
respondents agreed that they regularly provide patients with
information regarding side effects and how to effectively use repeat
antibiotic prescriptions, and guide patients to non-antibiotic
symptomatic therapy alternatives. These results can be compared
with the studies of Dyar et al. and Blanchette et al. confirming that
community pharmacists are playing an important role in patient
education, particularly about when and how to take prescribed
antibiotics [6,22]. The survey participants also reported that they
frequently intervene with prescribers if the dose, dosage form or
duration of antibiotic is not appropriate and if there is a potential of
drug interaction or allergy. However, pharmacists less frequently
intervene with prescribers regarding choice of antibiotics. These
results are similar to a study conducted in the USA regarding the role
of pharmacists, where most of the pharmacists could not change the
selection of antibiotics even knowing that it is not appropriate [23].
Thisfindingmayalsorelatetothelackofaccesstopatients’recordsby
pharmacists, thus not being aware of the exact diagnosis hindering
the pharmacist from contacting the prescriber. Presently, communi-
ty pharmacists in Australia cannot access patient’s clinical data to
confirm the appropriateness of prescribed antibiotics, but thereare a
number of initiatives taken recently by national and international
bodies aiming to improve community AMS practices. The most
recent of these in Australia is that pharmacists will be able to access
patients’electronichealthrecords[24].However,maximumbenefits
can only be achieved when complete information and ease of access
to these data is given to community pharmacists [25].
The majority of responding community pharmacists believe
that they can play an important role in AMS and can help reduce
inappropriate antibiotic use and healthcare costs. However, most
of the survey respondents did not agree that it would help in
further professional recognition or enhance their public image in
the community. It may be because there is no professional degree
or AMS course for specialisation in AMS. This is unlike the situation
in the USA [6], North America [26] and Europe [27] where AMS as a
specialised community pharmacy service is an emerging and
growing profession.
The major barriers identified in this survey were lack of access
to patients’ records and lack of any standard guideline to practice
AMS. Some of the respondents also highlighted the need for better
collaboration with GPs regarding dose, duration, dosage form and
particularly choice of antibiotic. In 2015, Bryant conducted a survey
in Australia and New Zealand which found that physicians and
pharmacists perceive lack of education, lack of dedicated staff, and
lack of willingness to change as reasons for slow implementation of
AMS [28].
The responses of the facilitators scale mirrored the responses of
the barriers scale. Most of the pharmacists agreed that professional
AMS training, public awareness campaigns, better pharmacist–GP
collaboration and access to patients’ records would be helpful in
effectively carrying out AMS activities.
4.2. Practice implications
The best AMS practices for community pharmacies in Australia,
like in many other countries, are not yet defined. The current studyprovides an insight into the practices, perceptions and awareness
of community pharmacists regarding AMS. These findings can help
overcome challenges related to the implementation of an effective
AMS model in the community. Most of the perceptions of
community pharmacists are directing us towards changing the
professional behaviours and systems for effective AMS activities.
Organisations interested in developing and implementing AMS
initiatives in community settings should consider addressing some
of the barriers identified in this study so that community
pharmacists can be engaged in such initiatives in a meaningful
way.
4.3. Limitations
Although responses were received from all the states and
territories of Australia, we acknowledge the limitations of
response bias thus limiting the generalisability of the findings.
Certain community pharmacists are less likely to respond to
online surveys, hence having only a limited spectrum of
respondents was one of the limiting factors of this study.
Similarly, it was difficult to take a representative sample
population based on visits to social media website and e-mail
links. Owing to an acceptable but low Cronbach’s α of the
perceived operational barriers and perceived facilitators scales,
there is a need that the questionnaire should be confirmed for
validity in another confirmatory survey.
5. Conclusions
Here we report the findings of a survey development and
validation study to measure the perceptions of Australian
community pharmacists regarding AMS. Once validated, the
survey tool may assist other researchers who are interested in
measuring the perceptions of community pharmacists about AMS
in their practice. Pharmacists in this study regarded their role as
antimicrobial stewards as an important one, although several
barriers related to the practice settings, patients’ perceptions and
their interaction with GPs were limiting their participation in AMS.
Organisations interested in implementing AMS initiatives in
community settings should address such barriers to encouraged
greater involvement of community pharmacists.
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